top of page

Xencor doses first patient in phase 1 clinical trial of XmAb14045

Xencor has dosed the first patient in a Phase 1 clinical trial of XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page